Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Clinical Trials Related to Neuroendocrine Tumors
Related studies linked through entity extraction aliases.
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
- Status
- COMPLETED
- Phase
- PHASE4
Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors
- Status
- TERMINATED
- Phase
- PHASE3
Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG
- Status
- COMPLETED
- Phase
- PHASE1
Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors
- Status
- TERMINATED
- Phase
- PHASE2
Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors
- Status
- COMPLETED
- Phase
- PHASE2
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)
- Status
- COMPLETED
- Phase
- PHASE4
Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
- Status
- COMPLETED
- Phase
- PHASE1
Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)
- Status
- COMPLETED
- Phase
- PHASE3
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
- Status
- COMPLETED
- Phase
- PHASE1
A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors
- Status
- COMPLETED
- Phase
- PHASE2
Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.
- Status
- COMPLETED
- Phase
- N/A
Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)
- Status
- COMPLETED
- Phase
- PHASE1
89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors
- Status
- COMPLETED
- Phase
- N/A
RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation
- Status
- COMPLETED
- Phase
- PHASE4
Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases
- Status
- COMPLETED
- Phase
- PHASE2
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
- Status
- COMPLETED
- Phase
- PHASE2